Todd P Gilmer1,2, Els van der Ven3,4, Ezra Susser3,5, Lisa B Dixon5,6, Mark Olfson3,5,6. 1. Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA. 2. Division of Health Policy, Vice Chair for Academic Affairs, Department of Family Medicine and Public Health, University of California, San Diego. 3. Mailman School of Public Health, Columbia University, New York, NY. 4. School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, Netherlands. 5. New York State Psychiatric Institute, New York, NY. 6. Vagelos College of Physicians & Surgeons, Columbia University, New York, NY.
Abstract
OBJECTIVE: To investigate patterns of mental health service and antipsychotic use following a first-episode schizophrenia (FES) and to examine the role of the treatment setting in which individuals are first diagnosed. METHOD: Analysis of de-identified administrative claims data from the OptumLabs Data Warehouse was used to identify 1450 privately insured youth and young adults aged 14 through 30 with FES from January 1, 2011 through December 31, 2015. Regression analysis was used to estimate the use of mental health services during the year following FES, by type of service and by site of index diagnosis. RESULTS: In the year following FES, 79.7% of youth received outpatient mental health services and 35.8% filled a prescription for antipsychotic medication. Among service users, mean outpatient visits were 15.9 and mean antipsychotic fills were 8.3. Youth who received an index diagnosis of FES in an inpatient setting were more likely to fill an antipsychotic medication than youth with FES in other settings. Youth who received an index diagnosis of FES during a specialty mental health outpatient visit had greater use of outpatient mental health than youth who received their diagnosis during a primary care visit. CONCLUSIONS: Despite evidence-based guidelines supporting outpatient psychosocial care and antipsychotic treatment for FES, one-fifth of this cohort did not use outpatient services and the majority did not fill any prescriptions for antipsychotic medications during the year following FES. Our findings provide renewed urgency to ongoing efforts to accelerate early identification and care coordination for youth with FES.
OBJECTIVE: To investigate patterns of mental health service and antipsychotic use following a first-episode schizophrenia (FES) and to examine the role of the treatment setting in which individuals are first diagnosed. METHOD: Analysis of de-identified administrative claims data from the OptumLabs Data Warehouse was used to identify 1450 privately insured youth and young adults aged 14 through 30 with FES from January 1, 2011 through December 31, 2015. Regression analysis was used to estimate the use of mental health services during the year following FES, by type of service and by site of index diagnosis. RESULTS: In the year following FES, 79.7% of youth received outpatient mental health services and 35.8% filled a prescription for antipsychotic medication. Among service users, mean outpatient visits were 15.9 and mean antipsychotic fills were 8.3. Youth who received an index diagnosis of FES in an inpatient setting were more likely to fill an antipsychotic medication than youth with FES in other settings. Youth who received an index diagnosis of FES during a specialty mental health outpatient visit had greater use of outpatient mental health than youth who received their diagnosis during a primary care visit. CONCLUSIONS: Despite evidence-based guidelines supporting outpatient psychosocial care and antipsychotic treatment for FES, one-fifth of this cohort did not use outpatient services and the majority did not fill any prescriptions for antipsychotic medications during the year following FES. Our findings provide renewed urgency to ongoing efforts to accelerate early identification and care coordination for youth with FES.
Authors: Jean Addington; Robert K Heinssen; Delbert G Robinson; Nina R Schooler; Patricia Marcy; Mary F Brunette; Christoph U Correll; Sue Estroff; Kim T Mueser; David Penn; James A Robinson; Robert A Rosenheck; Susan T Azrin; Amy B Goldstein; Joanne Severe; John M Kane Journal: Psychiatr Serv Date: 2015-01-15 Impact factor: 3.084
Authors: Óskar Hálfdánarson; Helga Zoëga; Lise Aagaard; Miquel Bernardo; Lena Brandt; Anna Coma Fusté; Kari Furu; Kristina Garuoliené; Falk Hoffmann; Krista F Huybrechts; Luuk J Kalverdijk; Koji Kawakami; Helle Kieler; Takuya Kinoshita; Melisa Litchfield; Soffy C López; Jorge E Machado-Alba; Manuel E Machado-Duque; Mufaddal Mahesri; Prasad S Nishtala; Sallie-Anne Pearson; Johan Reutfors; Leena K Saastamoinen; Izumi Sato; Catharina C M Schuiling-Veninga; Yu-Chiau Shyu; Svetlana Skurtveit; Hélène Verdoux; Liang-Jen Wang; Corinne Zara Yahni; Christian J Bachmann Journal: Eur Neuropsychopharmacol Date: 2017-07-27 Impact factor: 4.600
Authors: Iruma Bello; Rufina Lee; Igor Malinovsky; Liza Watkins; Ilana Nossel; Thomas Smith; Hong Ngo; Michael Birnbaum; Leslie Marino; Lloyd I Sederer; Marleen Radigan; Gyojeong Gu; Susan Essock; Lisa B Dixon Journal: Psychiatr Serv Date: 2016-12-15 Impact factor: 3.084
Authors: Gregory E Simon; Christine Stewart; Enid M Hunkeler; Bobbi Jo Yarborough; Frances Lynch; Karen J Coleman; Arne Beck; Belinda H Operskalski; Robert B Penfold; David S Carrell Journal: Am J Psychiatry Date: 2018-01-24 Impact factor: 18.112
Authors: Gregory E Simon; Christine Stewart; Bobbi Jo Yarborough; Frances Lynch; Karen J Coleman; Arne Beck; Belinda H Operskalski; Robert B Penfold; Enid M Hunkeler Journal: JAMA Psychiatry Date: 2018-03-01 Impact factor: 21.596